Research
Hormonal
Assessment of metabolic risk factors is critical in patients with NAFLD because advanced liver fibrosis correlates with metabolic comorbidities, and early identification of these factors prevents cardiovascular and liver-related mortality.
If you have NAFLD, focus on managing your metabolic health (blood sugar, blood pressure, weight) even if your liver enzymes look normal. This is the most effective way to protect your heart and liver from serious damage.
GoodSupportsHIGH confidence
Growing evidence supports that patients with NAFLD have increased cardiovascular morbidity and mortality. Moreover, advanced liver fibrosis is associated with increasing number of metabolic comorbidities. Thus, early identification and treatment of individual components of the metabolic syndrome are critical in preventing both cardiovascular and liver-related mortality.
Why this rating
Based on expert consensus and observational evidence cited in guidelines, not a specific RCT.
Source
Nonalcoholic Fatty Liver Disease and Recent Guideline Updates
Yumi Ando et al. · Clinical Liver Disease · 2021
DOI 10.1002/cld.1045
narrative_reviewCited 167×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Vitamin E is recommended for patients with NASH and advanced fibrosis who do not have diabetes, and pioglitazone is recommended for patients with NASH and diabetes.Good
- Systematic screening for NAFLD is not recommended by the AASLD even in high-risk populations due to lack of effective drug treatments, cost-effectiveness concerns, and unclear long-term benefits.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →